← Latest news 
Novo Nordisk eases insulin plan leaving a major opening for Eris and Biocon Biologics
Business
Published on 24 April 2026
A partial phase out could reshuffle India insulin supplies
Novo Nordisk’s partial phase out of a key insulin product in India may create a supply gap that competitors are ready to fill. Eris Pharma and its contract manufacturing partner Biocon Biologics could benefit as demand shifts and procurement patterns adjust. The move could trigger pricing and market share changes across India’s insulin landscape, with near-term opportunities for local players.
- Novo Nordisk is partially phasing out a major insulin product
- Eris Pharma and Biocon Biologics are positioned to gain from the gap
- India insulin demand may be redistributed among available brands
- Potential impact includes pricing and market share shifts
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times